Nomination Committee Functions and Best Practices for Hong Kong Issuers

The HKEX’s 2024 consultation on board effectiveness, which concluded in Q1 2025, has placed the nomination committee under a sharper regulatory microscope. While the existing Listing Rules have long mandated a nomination committee for Main Board issuers (Rules 3.25-3.27A), the market’s focus has shifted from mere establishment to operational rigour. The SFC’s 2024 enforcement report noted that 12% of investigated governance failures involved director appointment processes that lacked documented, objective criteria. For issuers preparing for an IPO in 2025-2026, the nomination committee is no longer a compliance checkbox; it is a critical gatekeeper for board composition, succession planning, and ultimately, investor confidence. A poorly structured committee can delay a listing or, post-IPO, trigger a regulatory inquiry that erodes market trust. This article dissects the mandatory functions, best practices, and common pitfalls for Hong Kong issuers, drawing directly on the Listing Rules, the Corporate Governance Code (CG Code), and recent market observations.

Mandatory Functions Under the Listing Rules and CG Code

The nomination committee’s core mandate is defined by HKEX Listing Rules 3.25 to 3.27A and the CG Code provisions (specifically Code Provisions B.3.1 to B.3.7). These are not aspirational guidelines; they are binding requirements for all Main Board issuers.

Director Nomination and Re-election

The committee’s primary function is to identify, assess, and recommend candidates for directorship. This process must be formalised in written terms of reference, which the board must approve (Rule 3.25). The committee must establish a nomination policy that includes objective criteria for assessing board composition, such as skills, experience, independence, and diversity (CG Code B.3.1). For IPO applicants, the sponsor must confirm that the nomination committee has been formed and has adopted such a policy before the listing date. The HKEX’s 2023 guidance note on board diversity explicitly requires the committee to consider measurable targets for gender diversity at both the board and senior management levels.

Annual Board Evaluation and Succession Planning

The CG Code requires the nomination committee to conduct an annual review of the board’s structure, size, and composition (B.3.2). This review must include an assessment of the balance of skills, experience, and diversity. The committee must also lead the process for board and individual director evaluations, the results of which must be disclosed in the corporate governance report. Succession planning is a specific duty: the committee must formulate plans for orderly succession to the board, particularly for the chairperson and the chief executive (B.3.5). For a pre-IPO issuer, this means having a documented succession plan for at least the CEO and board chair, covering both planned retirement and unexpected departure scenarios.

Independence Assessment

The nomination committee is responsible for annually assessing the independence of each independent non-executive director (INED). This assessment must go beyond a mechanical check of the nine objective criteria in Rule 3.13. The committee must consider qualitative factors, including the director’s character, judgment, and any relationships that might impair independence. The HKEX’s 2024 consultation proposed enhanced disclosure of this qualitative assessment, and the final rules, expected in late 2025, will likely require a more detailed explanation in the annual report. For issuers with a long-serving INED (over nine years), the committee must provide a reasoned justification for their continued independence in the circular to shareholders (Rule 3.13).

Best Practices for Pre-IPO and Newly Listed Issuers

For companies at the IPO preparation stage, the nomination committee is often a newly formed body. Its effectiveness is directly scrutinised by the HKEX during the listing vetting process.

Establishing a Robust Nomination Policy

The nomination policy must be a living document, not a boilerplate template. Best practice dictates that the policy should include: (i) a skills matrix identifying gaps on the current board; (ii) a diversity policy with measurable targets (e.g., at least one female director by the first annual general meeting post-listing); (iii) a procedure for handling director resignations and appointments between AGMs; and (iv) a process for considering shareholder nominations. The HKEX Listing Decision LD119-2017 (a real case) highlighted that a board’s failure to articulate a clear rationale for a director’s appointment, despite having a policy, constituted a breach of the CG Code. The policy should be approved by the full board and reviewed annually.

Committee Composition and Independence

The nomination committee must have a majority of INEDs and be chaired by the board chairperson or an INED (Rule 3.25). For IPO applicants, the committee should be formed at least three months before the expected listing date to allow for a proper meeting cycle. The committee chair should not be the same person as the chair of the remuneration committee, to avoid concentration of power. The company secretary should act as secretary to the committee, ensuring minutes are comprehensive and record the rationale for all decisions, including dissenting views. Minutes should be circulated to the full board within 14 days of the meeting.

Meeting Cadence and Documentation

A common deficiency observed by the HKEX in its 2023 review of board practices was that nomination committees met only once a year, typically to approve the circular for the AGM. This is insufficient. Best practice dictates at least two meetings per year: one to review the annual board evaluation and succession plan, and a second to consider director nominations for the AGM. Additional meetings should be convened for any ad-hoc appointments. All meetings must have a formal agenda circulated at least seven days in advance, and minutes must record attendance, decisions, and the basis for those decisions. For a pre-IPO issuer, the sponsor will review these minutes as part of its due diligence.

Common Pitfalls and Regulatory Scrutiny

The SFC and HKEX have increasingly focused on the nomination committee’s role in preventing governance failures.

Failure to Address Board Diversity

The HKEX’s 2024 review of board diversity compliance found that while 98% of Main Board issuers had a diversity policy, only 62% had disclosed measurable targets. The nomination committee is responsible for setting these targets and monitoring progress. A failure to achieve a stated target (e.g., having at least one female director by a certain date) must be explained in the corporate governance report. The committee should not simply state “we are working on it”; a specific timeline and action plan are required. For IPO applicants, the prospectus must disclose the board’s diversity policy and the steps taken to implement it. A vague or absent policy can lead to a formal comment letter from the HKEX.

Inadequate Succession Planning for INEDs

A recurring issue in enforcement cases is the sudden departure of an INED, leaving the board without a qualified replacement for months. The nomination committee must maintain a “bench” of potential candidates, pre-vetted for independence and skills. The committee should proactively identify potential successors for each INED, especially the chair of the audit committee, who must have relevant financial expertise (Rule 3.21). The succession plan should be a standing agenda item at every committee meeting, not just an annual review. The HKEX’s 2022 enforcement against a Main Board issuer for failing to replace a resigning audit committee chair within three months (a breach of Rule 3.21) underscores the cost of poor planning.

Conflicts of Interest in the Nomination Process

The nomination committee must guard against the nomination of directors who are connected to substantial shareholders or management without proper disclosure. The committee should require each candidate to complete a detailed questionnaire covering their relationships with the issuer, its subsidiaries, and its major shareholders. This information must be disclosed in the circular to shareholders. The SFC’s 2023 enforcement action against a company where a nominee was a close relative of a controlling shareholder, but was presented as independent, resulted in a public reprimand and a fine. The committee must verify independence declarations independently, not rely solely on the candidate’s self-assessment.

The Evolving Role in ESG and Stakeholder Engagement

The CG Code’s 2022 amendments, which took effect for financial years beginning on or after 1 January 2022, explicitly linked the nomination committee’s work to the issuer’s ESG strategy.

Integrating ESG Competencies into Board Composition

The nomination committee is now expected to assess the board’s collective skills in relation to the issuer’s ESG risks and opportunities. For a pre-IPO issuer in a sector with material environmental or social risks (e.g., manufacturing, energy, or financial services), the skills matrix should include ESG expertise. The committee should consider whether the board has a director with experience in climate risk management, human rights, or sustainable finance. This is not a mandatory requirement, but it is a clear expectation from the HKEX, as stated in its 2023 guidance on board effectiveness. The committee should document how ESG competencies were considered in the nomination process.

Engaging with Shareholders on Board Composition

The nomination committee should establish a formal policy for handling shareholder nominations for directors. While the issuer’s articles of association may set thresholds for shareholder proposals, the committee should proactively engage with significant shareholders (those holding 5% or more) to understand their views on board composition. The committee chair should be available to meet with institutional investors, particularly during the AGM period. The HKEX’s 2024 consultation on shareholder communication emphasised that the nomination committee should consider the outcome of the annual general meeting vote on director re-election as a key input for its annual board evaluation. A high number of votes against a director’s re-election should trigger a review by the committee.

Actionable Takeaways for CFOs and Company Secretaries

1. Finalise the nomination policy and skills matrix at least six months before the expected listing date, ensuring it includes measurable diversity targets and a process for handling shareholder nominations, and have it reviewed by the sponsor.

2. Schedule the nomination committee to meet at least twice a year, with the first meeting dedicated to the annual board evaluation and succession plan, and the second to director nominations for the AGM, with minutes recording the rationale for all decisions.

3. Conduct a qualitative independence assessment for each INED annually, documenting the factors considered beyond the nine objective criteria in Rule 3.13, and prepare a justification for any INED serving beyond nine years.

4. Integrate ESG competencies into the board skills matrix, and document how these competencies were considered in the nomination process for any new director appointment.

5. Establish a formal shareholder engagement policy for board composition, including a process for receiving and evaluating shareholder nominations, and ensure the committee chair is available for meetings with institutional investors.